112 related articles for article (PubMed ID: 22584215)
1. Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers.
Domingo L; Blanch J; Servitja S; Corominas JM; Murta-Nascimento C; Rueda A; Redondo M; Castells X; Sala M
Eur J Cancer Prev; 2013 Jan; 22(1):21-8. PubMed ID: 22584215
[TBL] [Abstract][Full Text] [Related]
2. Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study.
Rayson D; Payne JI; Abdolell M; Barnes PJ; MacIntosh RF; Foley T; Younis T; Burns A; Caines J
Clin Breast Cancer; 2011 Mar; 11(1):27-32. PubMed ID: 21421519
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain.
Domingo L; Sala M; Servitja S; Corominas JM; Ferrer F; Martínez J; Macià F; Quintana MJ; Albanell J; Castells X
Cancer Causes Control; 2010 Aug; 21(8):1155-64. PubMed ID: 20349271
[TBL] [Abstract][Full Text] [Related]
4. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
[TBL] [Abstract][Full Text] [Related]
5. The role of mammography screening attendance and detection mode in predicting breast cancer survival-is there added prognostic value?
Biesheuvel C; Czene K; Orgeás CC; Hall P
Cancer Epidemiol; 2011 Dec; 35(6):545-50. PubMed ID: 21470933
[TBL] [Abstract][Full Text] [Related]
6. Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes.
Kim J; Lee S; Bae S; Choi MY; Lee J; Jung SP; Kim S; Choe JH; Kim JH; Kim JS; Lee JE; Nam SJ; Yang JH
Breast Cancer Res Treat; 2012 Jan; 131(2):527-40. PubMed ID: 22042364
[TBL] [Abstract][Full Text] [Related]
7. Late-stage breast cancer among women with recent negative screening mammography: do clinical encounters offer opportunity for earlier detection?
Mouchawar J; Taplin S; Ichikawa L; Barlow WE; Geiger AM; Weinmann S; Gilbert J; Manos MM; Ulcickas Yood M
J Natl Cancer Inst Monogr; 2005; (35):39-46. PubMed ID: 16287884
[TBL] [Abstract][Full Text] [Related]
8. Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival.
Porter GJ; Evans AJ; Cornford EJ; Burrell HC; James JJ; Lee AH; Chakrabarti J
AJR Am J Roentgenol; 2007 Mar; 188(3):676-83. PubMed ID: 17312053
[TBL] [Abstract][Full Text] [Related]
9. Update of the Swedish two-county program of mammographic screening for breast cancer.
Tabàr L; Fagerberg G; Duffy SW; Day NE; Gad A; Gröntoft O
Radiol Clin North Am; 1992 Jan; 30(1):187-210. PubMed ID: 1732926
[TBL] [Abstract][Full Text] [Related]
10. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.
Shen Y; Yang Y; Inoue LY; Munsell MF; Miller AB; Berry DA
J Natl Cancer Inst; 2005 Aug; 97(16):1195-203. PubMed ID: 16106024
[TBL] [Abstract][Full Text] [Related]
11. Survival and Disease-Free Survival by Breast Density and Phenotype in Interval Breast Cancers.
Sala M; Domingo L; Louro J; Torá-Rocamora I; Baré M; Ferrer J; Carmona-Garcia MC; Barata T; Román M; Macià F; Castells X;
Cancer Epidemiol Biomarkers Prev; 2018 Aug; 27(8):908-916. PubMed ID: 29853482
[No Abstract] [Full Text] [Related]
12. Interval breast cancers: prognostic features and survival by subtype and time since screening.
Porter GJ; Evans AJ; Burrell HC; Lee AH; Ellis IO; Chakrabarti J
J Med Screen; 2006; 13(3):115-22. PubMed ID: 17007651
[TBL] [Abstract][Full Text] [Related]
13. Minority report - false negative breast assessment in women recalled for suspicious screening mammography: imaging and pathological features, and associated delay in diagnosis.
Ciatto S; Houssami N; Ambrogetti D; Bonardi R; Collini G; Del Turco MR
Breast Cancer Res Treat; 2007 Sep; 105(1):37-43. PubMed ID: 17115112
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study.
Musolino A; Michiara M; Conti GM; Boggiani D; Zatelli M; Palleschi D; Bella MA; Sgargi P; Di Blasio B; Ardizzoni A
J Clin Oncol; 2012 Jul; 30(19):2362-8. PubMed ID: 22585698
[TBL] [Abstract][Full Text] [Related]
15. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers.
Crosier M; Scott D; Wilson RG; Griffiths CD; May FE; Westley BR
Clin Cancer Res; 1999 Oct; 5(10):2682-8. PubMed ID: 10537329
[TBL] [Abstract][Full Text] [Related]
16. Prognostic importance of palpability as a feature of screen-detected breast cancers.
Gill G; Luke C; Roder D
J Med Screen; 2006; 13(2):98-101. PubMed ID: 16792834
[TBL] [Abstract][Full Text] [Related]
17. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
18. Mammography screening for breast cancer in Copenhagen April 1991-March 1997. Mammography Screening Evaluation Group.
Lynge E
APMIS Suppl; 1998; 83():1-44. PubMed ID: 9850674
[TBL] [Abstract][Full Text] [Related]
19. Socioeconomic inequalities in attending the mass screening for breast cancer in the south of the Netherlands--associations with stage at diagnosis and survival.
Aarts MJ; Voogd AC; Duijm LE; Coebergh JW; Louwman WJ
Breast Cancer Res Treat; 2011 Jul; 128(2):517-25. PubMed ID: 21290176
[TBL] [Abstract][Full Text] [Related]
20. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program.
Baré M; Torà N; Salas D; Sentís M; Ferrer J; Ibáñez J; Zubizarreta R; Sarriugarte G; Barata T; Domingo L; Castells X; Sala M
Breast Cancer Res Treat; 2015 Nov; 154(2):403-15. PubMed ID: 26531756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
